NM · State regulatory reference
New Mexico.
Moderate
New Mexico permits telehealth with the physician-patient relationship established electronically: the Medical Board's Medical Ethics rule (16.10.8.8 NMAC) allows treatment during a synchronous audio-video telehealth encounter where a history and informed consent are obtained, and permits waiving the physical exam where one would not normally be part of the in-person encounter. Compounding under 16.19.30 NMAC (USP <795>, non-sterile) and 16.19.36 NMAC (USP <797>, sterile) mirrors federal standards with no NM-specific GLP-1 restriction. No documented NM board enforcement against peptide/GLP-1 compounding was found (only a Department of Justice consumer advisory).
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
An initial visit and prescribing may occur via synchronous audio-video under 16.10.8.8 NMAC (Medical Ethics), which treats a videoconference encounter with history and informed consent as sufficient to establish the relationship and allows waiving the physical exam where clinically appropriate.
Compounding
NM Board of Pharmacy rules mirror federal standards — 16.19.30 NMAC (USP <795>, non-sterile) and 16.19.36 NMAC (USP <797>, sterile) — with no state-specific GLP-1/semaglutide restriction beyond a general prohibition on compounding safety-withdrawn drugs.
Sources